



The human immunodeficiency virus (HIV) infection is a 
major community health concern with significant morbidity 
and mortality.[1] The prevalence of HIV infection is reported to 
be high in Africa in 2017. It was estimated to be 25.7 million, 
constituting 70.0% of the 36.9 million people infected 
with HIV/acquired immunodeficiency syndrome (AIDS) 
globally.[2] Nigeria is ranked second among countries with the 
leading HIV epidemics worldwide due to its large population 
size. It had a national prevalence of 1.5% and estimated 
population of 1.9 million individuals living with HIV/AIDS 
in 2018.[3,4]
There is a substantial reduction in the disease and death of 
People Living with HIV/AIDS (PLWHA) in the past decade 
following the initiation and implementation of combined 
antiretroviral therapy (cART).[5] The ultimate aim of cART is 
to achieve the utmost and lasting repression of viral replication, 
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which manifests as improved quality of life and prolonged life 
expectancy.[6]
Notwithstanding these achievements, there are problems 
associated with the use of cART, which include poor drug 
adherence, high pill burden, adverse drug reactions, and risks of 
renal and hepatic impairments.[7,8] Pill burden is the number of 
pills in the form of tablets, capsules, or other dosage forms that 
are regularly taken by a patient.[9] A high pill burden is known 
to be associated with poor drug adherence, particularly among 
individuals with chronic diseases.[10,11] The World Health 
Organization, defined medication adherence as the degree that 
a person’s conduct toward medication utilization, effecting 
lifestyle changes, and complying with a diet agrees with 
approved instruction from a health-care provider.[12] Several 
methods are used to assess medication adherence, which 
include refill rates, therapeutic drug monitoring, self‑report 
survey form, and electronic devices. A combination of various 
methods has been recommended as a modern approach for 
assessing adherence.[13] Adherence to cART is essential to 
achieve durable clinical outcomes in PLWHA. Cohen et al. 
recorded an elevated risk of incomplete viral suppression 
in patients having poor adherence to cART. This can lead to 
viremia and potentially increase the risk for disease progression 
and untimely death.[10]
Despite the enormous challenges posed by poor adherence and 
pill burden to individuals with chronic illnesses, little is known 
about the magnitude of these drug therapy problems among 
PLWHA in Nigeria. We, therefore, evaluated cART-related 
problems among PLWHA and focused on their medication 
adherence and pill burden.
Methods
Study design
This study is a cross-sectional observational study involving 
PLWHA receiving cART at the AIDS Prevention Initiative 
in Nigeria (APIN) clinic, Lagos University Teaching 
Hospital (LUTH). PLWHA who presented consecutively 
to the clinic were recruited over a four-month period, 
between  September 1, 2017, and December 31, 2017. LUTH 
is an 800-bedded capacity tertiary health facility situated in 
Lagos, Nigeria. The hospital provides tertiary care for over 20 
million residents of Lagos and its environs.
Study population and sampling technique
We recruited 296 PLWHA on cART who were attending the 
APIN clinic using a convenient sampling method. Patients 
were enrolled in the study if ≥18 years old, were HIV infected, 
on cART for ≥3 months, and willing to give informed consents. 
Patients who were non-consenting, critically ill, pregnant, 
or <18 years old were excluded.
Sample size
We calculated sample size using Raosoft® online calculator (with 
a power of 95% confidence level, response distribution 
set at 50%, error margin of 6%, and a population size of 
18,100 registered patients as of 2017). A sample size of 263 was 
obtained through the calculation which was increased to 296 to 
make up for 10% attrition.
Data collection and study instrument
Eligible patients were interviewed with the aid of a 
well-structured questionnaire. The questionnaire was 
self-designed and adapted from the various studies evaluating 
adherence and pill burdens among adults with chronic 
illnesses,[7,8] and other studies evaluating drug therapy 
problems in PLWHA.[10,11] The instrument was validated 
by experts in the fields of clinical pharmacology and 
pharmacoepidemiology. It was pretested at the HIV Clinic, 
General Hospital Ikorodu, among PLWHA receiving treatment 
at the center. Any ambiguity and questions that were difficult 
for the participants to understand were simplified and modified 
before the questionnaire was used in the study proper. The 
questionnaire was interviewer administered in which a trained 
interviewer asked questions from each eligible patient in 
English Language or Pidgin English. Information sought 
included sociodemographics (age, sex, level of education, 
marriage status, employment standing, and once-a-month 
income). Clinical information about the patients was extracted 
from the case notes and included confirmation of HIV 
infection, presence of comorbidities, type of cART regimen 
used by the patients, concomitant medications used to treat 
the comorbidities, number of pills taken per day, and baseline 
CD4 count. Medication adherence was evaluated with the 
four-item Morisky Medication Adherence Scale (MMAS). 
The following were the questions asked: (1) Do you forget 
to take your medications? (2) Are you careless about time 
of taking your medications? (3) Do you stop taking your 
medications when you feel better? and (4) Do you stop taking 
your medications when you feel worse? These questions were 
asked if they occurred over the last six months. The answers 
were scored by giving each “yes” reply a score of 1 and each 
“no” reply was given a score of 0. The good adherent group 
had 0 mark and poor adherent group had 1–4 marks. The 
main outcome measures were (a) the adherence level over six 
month’s period as defined by complete negative answers to all 
MMAS questions and (b) the level of pill burden as defined 
by the number of pills >5/day among PLWHA.
Ethical approval
The LUTH Health Research Ethics Committee (HREC) gave 
approval for the study with a reference No. ADM/DCST/HREC/
APP/1046. Consent of all people who took part in the study 
was obtained.
Statistical analysis
We analyzed data obtained using the Statistical Package for 
the Social Sciences (SPSS®), version 20, Chicago, Illinois, 
United States. The categorical data were reported as percentage 
and proportion, while continuous variables were presented as 
median (interquartile range [IQR]). The sociodemographic 
features for adherence categories were compared using simple 
descriptive statistics. The categorical variables for patients with 
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good and poor adherence were compared using Fisher’s exact 
tests or Chi-square, while the Mann–Whitney test was used for 
continuous variables since they were not normally distributed. 
Multivariate analysis was done to determine the independent 
risk factors for poor adherence. Any P ≤ 0.05 was regarded to 
be statistically significant.
results
We evaluated 296 patients who completed the study. There 
were more females (219; 74.0%) than males (77; 26.0%) in 
this study with a female:male ratio of 2.8:1. Table 1 shows 
the sociodemographic and clinical characteristics of PLWHA 
receiving cART. The median (IQR) age of the patients was 
40 (35.0–47.7) years. Majority were married (262; 88.5%), 
in employment (267; 90.2%) and had at least a secondary 
school education (142; 48.0%). Majority (256; 86.5%) had 
no comorbidities, but among the few with comorbidities, 
hypertension was the most  common (13; 4.4%). 
Majority (247; 83.4%) of the patients had good adherence 
to cART resulting in a poor adherence rate of 16.6%. Pill 
burden exceeding 5 pills/day was observed in 36 (12.2%) 
patients. Majority (215; 72.6%) of the patients had a CD4 
count >500 cells/mL.
Pattern of adherence to combined antiretroviral therapy 
in people living with human immunodeficiency virus/
acquired immunodeficiency syndrome
Table 2 shows the comparison of clinical characteristics of 
PLWHA that had good and poor adherence to cART and 
their socio-demographics. Poor adherence was statistically 
significantly associated with a higher frequency of pill 
burden (P < 0.001) but not with the use of fixed-dose 
combinations (P < 0.001). There was, however, no 
statistically significant difference in age, gender, marital 
status, employment status, level of education, commodity 
pattern, and CD4 count. Figure 1 shows the reasons for 
poor adherence among PLWHA. Forgetting to take pills (44; 
16.5%) was the most common reason for poor adherence 
AQ4
followed by being too busy to take pills (10.5%) and traveling 
without pills (3.7%).
Prescription pattern of combined antiretroviral therapy 
for people living with human immunodeficiency virus/
acquired immunodeficiency syndrome
Majority (259; 86.5%) of the patients were using fixed‑dose 
combination. Table 3 shows the pattern of cART regimen 
combinations used by PLWHA.
Independent predictor of nonadherence
Being female, presence of comorbidity, not receiving fixed‑dose 
combination, and CD4 count level were not independent 
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Table 1: Sociodemographic and clinical characteristics of 
human immunodeficiency virus-infected patients receiving 
antiretroviral drugs
Variable Frequency (%)





































**Adherence: MMAS score of 0, *Pill burden: >5 pill/day, Others: 
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Figure 1: Reasons for nonadherence among human immunodeficiency 
virus‑infected patients
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Table 3: Pattern of antiretroviral regimen combinations 






Boosted PI 3 (1.01)
Combination regimen
Fixed-dose combo 3 257 (86.82)
Fixed-dose combo 2 27 (9.12)







NRTI: Nucleoside or nucleotide reverse transcriptase inhibitor, 
NNRTI: Non-NRTI, PI: Protease inhibitor, ART: Antiretroviral therapy
predictors of poor adherence to cART. Table 4 shows a 
multivariate analysis of the predictors of poor adherence to 
cART. Only pill burden >5/day was found to be independently 
associated with poor adherence (odd ratio = 0.67, confidence 
interval = 0.03–1.66, P < 0.001).
dIscussIon
Studies have shown that treatments with cART are limited by 
drugs-related problems such as poor adherence, pill burden, 
adverse drug reactions, impairment of renal function, and 
hepatotoxicity.[11] In this study, we reported good adherence 
to cART which was observed in 83.4% of the patients. 
On the contrary, we observed a high proportion of pill 
burden >5 pills/day in 12.2% of the patients. Medication 
adherence is a strong‑willed behavior. It is influenced by 
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factors that are associated with quality of health-care delivery, 
patient-related variables, patient–health-care provider 
interconnection, and treatment regimen complexity.[14] Good 
adherence to cART ranges between 63% and 93% worldwide, 
which was based on the assessment methods used. The rate is 
higher in developed than in developing countries.[15,16]
We observed 83.4% adherence in our study. This is 
similar to those reported in two separate studies from 
Ethiopia.[17,18] By contrast, our finding was slightly higher than 
the 75.5%–78.0% reported in a smaller population of PLWHA 
attending a teaching hospital in Kano, Northern Nigeria,[8] and 
another public hospital in India.[19] These varied adherence 
rates may be attributed to the methodological differences in 
assessing adherence. Other factors that may explain the diverse 
adherence rates include socioeconomic levels of the patients, 
location of the study, and level of adherence counseling 
received by the patients.
Poor adherence to cART in our study was associated with 
forgetfulness to take pills, being too busy to take pills, traveling 
without pills, exhaustion of pills without refill, and adverse 
effects of the pills. Similar factors had been reported to promote 
poor adherence to cART in other studies.[8,20] Cohen et al. 
reported that a high pill burden, characterized by the use of 
multiple cART, was associated with lower rates of complete 
adherence in the United States, consequently, resulting in a 
higher overall health-care cost for PLWHA.[10] Despite cART 
being considered to be very convenient for PLWHA, the regimen 
remains a lifelong treatment for this population group. Therefore, 
PLWHA are expected to be prescribed different medications 
that are related to HIV infection or other comorbid conditions 
thereby increasing the medication pill for this group of patients.
A comparatively high burden of medication among PLWHA 
compared to their uninfected counterparts was reported in 
Table 2: Comparison of sociodemographic and clinical 
characteristics of human immunodeficiency virus-infected 







Median age (IQR) years 40 (35-48) 40 (35-47) 0.60
Gender
Male 63 (25.50) 14 (28.60) 0.72
Female 184 (74.50) 35 (71.40)
Marital status
Single 17 (6.90) 5 (10.20) 0.69
Married 220 (89.10) 42 (85.70)
Divorced 2 (0.80) 1 (2.00)
Widowed 8 (3.20) 1 (2.00)
Employment status
Employed 222 (89.90) 45 (91.80) 0.79
Unemployed 25 (10.10) 4 (8.20)
Educational level
None 11 (4.50) 0 (0.00) 0.33
Primary 39 (15.80) 10 (20.40)
Secondary 121 (49.00) 21 (42.90)
Tertiary 76 (30.80) 18 (36.70)
Comorbidity pattern
None 213 (86.20) 43 (87.80) 0.70
Hypertension 10 (4.00) 3 (6.10)
Diabetes 5 (2.00) 0
Others 19 (7.70) 3 (0)
Comorbidity
Yes 34 (13.77) 6 (12.24) <0.00*
No 213 (86.23) 43 (87.75)
Pill burden
Yes 2 (0.81) 34 (69.38) <0.00*
No 245 (99.19) 15 (30.61)
Fixed-dose combination
Yes 243 (98.38) 16 (32.65) 0.22
No 4 (1.61) 33 (67.34)
CD4 count (cells/ml)
<500 65 (26.30) 16 (32.70) 0.36
>500 182 (73.70) 33 (67.30)
*Significant. IQR: Interquartile range
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Table 4: Multivariate analysis of predictors of 
nonadherence
Variable OR 95% CI P
Gender (female) 0.71 0.26-13.44 0.69
Comorbidity (yes) 2.32 1.21-5.82 0.44
Pill burden >5/day 0.67 0.03-1.66 <0.00*
Fixed dose combination (no) 1.19 0.01-3.87 0.83
CD4 count (cells/ml) <500 0.37 0.04-0.79 0.57
*Significant. OR: Odd ratio, CI: Confidence interval
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studies conducted in Canada and Switzerland.[21] We reported 
a pill burden of over five pills a day in more than one‑tenth 
of our patients. A study by Zhou et al. that assessed PLWHA 
total daily pill burden in the Southern United States reported 
eight pills (IQR: 6–11) as the median number of medications 
per patient.[22] The Zhou study observed that a significantly 
huge pill burden of over 10 pills/day was associated with the 
presence of more than three comorbidities in PLWHA. The 
high number of comorbidities among PLWHA in the Zhou 
study may account for the high pill burden compared to ours. 
Nonetheless, we observed that a pill burden of >5 pills/day 
was a predictor of poor adherence to cART similarly reported 
by Cohen et al.[11] and Zhou et al.[22]
We found no direct association between sociodemographic 
characteristics of PLWHA and medication adherence compared 
to previous studies that reported an association.[8,10,22] Our 
study is characterized by some limitations such as being a 
single-center study, which makes it impossible to generalize 
our findings among the entire population of PLWHA in Nigeria. 
Furthermore, we used a self-reporting adherence evaluation 
method (MMAS) compared to an observational pill counting 
method that genuinely assessed adherence. Therefore, we may 
have overestimated or underestimated adherence in our study. 
Notwithstanding these limitations, our study has provided 
some important clinical findings that are helpful to clinicians 
in exploring measures to improve adherence to ARV drugs and 
to lessen the pill burden.
conclusIon
Drug adherence and pill burden are important cART-related 
problems observed among PLWHA. Although a good 
adherence level to cART was observed in this study, 
the proportion of patients exhibiting poor adherence is 
concerning and needs to be improved. Pill burden was a 
predictor of poor adherence; therefore, measures to reduce 
this problem and to improve the level of adherence to cART 
are hereby advocated.
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